Immupharma PLC Total Voting Rights (0957W)

TIDMIMM

RNS Number : 0957W

Immupharma PLC

16 August 2022

RNS | 16 August 2022

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the de nominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

 
 ImmuPharma PLC ( www.immupharma.com ) 
  Tim McCarthy, Chief Executive Officer & 
  Chairman                                      + 44 (0) 207 152 4080 
 
 Lisa Baderoon, Head of Investor Relations 
  & Non-Executive Director                      + 44 (0) 7721 413496 
 SPARK Advisory Partners Limited (NOMAD) 
  Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
  Stanford Capital Partners (Joint Broker) 
  Patrick Claridge, John Howes, Bob Pountney     +44 20 3650 3650 
 
  SI Capital (Joint Broker) 
  Nick Emerson                                   +44 (0) 1483 413500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSFIESIEESEEA

(END) Dow Jones Newswires

August 16, 2022 03:03 ET (07:03 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024